Label: IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE solution

  • NDC Code(s): 0487-0201-01, 0487-0201-02, 0487-0201-03, 0487-0201-60
  • Packager: Nephron Pharmaceuticals Corporation
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated April 8, 2025

If you are a consumer or patient please visit this version.

  • *Equivalent to 2.5 mg albuterol base.
  • DESCRIPTION
    The active components in Ipratropium Bromide and Albuterol Sulfate Inhalation Solution, USP are albuterol sulfate, USP and ipratropium bromide, USP. Albuterol sulfate is a salt of racemic ...
  • CLINICAL PHARMACOLOGY
    Ipratropium Bromide and Albuterol Sulfate Inhalation Solution is a combination of the β 2-adrenergic bronchodilator, albuterol sulfate, and the anticholinergic bronchodilator, ipratropium ...
  • ANIMAL PHARMACOLOGY & OR TOXICOLOGY
    Albuterol Sulfate - Intravenous studies in rats with albuterol sulfate have demonstrated that albuterol crosses the blood-brain barrier and reaches brain concentrations amounting to ...
  • CLINICAL STUDIES
    In a 12-week, randomized, double-blind, positive-control, crossover study of albuterol sulfate, ipratropium bromide and Ipratropium Bromide and Albuterol Sulfate Inhalation Solution, 863 COPD ...
  • INDICATIONS AND USAGE
    Ipratropium Bromide and Albuterol Sulfate Inhalation Solution is indicated for the treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator.
  • CONTRAINDICATIONS
    Ipratropium Bromide and Albuterol Sulfate Inhalation Solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.
  • WARNINGS
    PARADOXICAL BRONCHOSPASM - In the clinical study of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution, paradoxical bronchospasm was not observed. However, paradoxical bronchospasm ...
  • PRECAUTIONS
    General - 1. Effects Seen with Sympathomimetic Drugs - As with all products containing sympathomimetic amines, Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be used ...
  • ADVERSE REACTIONS
    Adverse reaction information concerning Ipratropium Bromide and Albuterol Sulfate Inhalation Solution was derived from the 12-week controlled clinical trial. Additional adverse reactions ...
  • OVERDOSAGE
    The effects of overdosage with Ipratropium Bromide and Albuterol Sulfate Inhalation Solution are expected to be related primarily to albuterol sulfate, since ipratropium bromide is not well ...
  • DOSAGE AND ADMINISTRATION
    The recommended dose of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution is one 3 mL vial administered 4 times per day via nebulization with up to 2 additional 3 mL doses allowed per ...
  • HOW SUPPLIED
    Ipratropium Bromide and Albuterol Sulfate Inhalation Solution, USP is supplied as a 3 mL sterile solution for nebulization in sterile low-density polyethylene unit-dose vials. Store vials in pouch ...
  • Patient Package Insert
    Read this patient information completely every time your prescription is filled as information may have changed. Keep these instructions with your medication as you may want to read them ...
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
    Principle Display – Pouch (5 Vial Card) NDC 0487-0201-03, NDC 0487-0201-60 - Principle Display – Carton (30 Count) NDC 0487-0201-03 - Principle Display – Carton (60 Count) NDC ...
  • INGREDIENTS AND APPEARANCE
    Product Information